Literature DB >> 27951570

Biocompatibility of Hemodiafilters.

Tadashi Tomo1.   

Abstract

BACKGROUND: Biocompatibility and the efficiency of solute removal are important considerations in blood purification therapy. Improvement of biocompatibility is expected to lead to the prevention of dialysis-related complications (e.g. amyloidosis, arteriosclerosis, and malnutrition) and to the delay of disease progression by alleviating microinflammation.
SUMMARY: The biocompatibility of dialyzers is greatly influenced by the interaction between blood and the treatment materials, in which the chemical and physical characteristics of membrane materials play important roles. In hemodiafiltration (HDF), treatment characteristics such as dilution modes are also considered to greatly affect this interaction between blood and materials. Studies have reported that the levels of C-reactive protein are decreased in patients receiving HDF. Thus, the improvement of biocompatibility is an important factor in HDF. Key Messages: To improve the biocompatibility of HDF, it is essential to improve the biocompatibility of hemodiafilters. This article outlines the importance of biocompatibility and related factors in HDF.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27951570     DOI: 10.1159/000450803

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  3 in total

Review 1.  Vitamin E (Alpha-Tocopherol) Metabolism and Nutrition in Chronic Kidney Disease.

Authors:  Francesco Galli; Mario Bonomini; Desirée Bartolini; Linda Zatini; Gianpaolo Reboldi; Giada Marcantonini; Giorgio Gentile; Vittorio Sirolli; Natalia Di Pietro
Journal:  Antioxidants (Basel)       Date:  2022-05-18

Review 2.  Biocompatibility of Surface-Modified Membranes for Chronic Hemodialysis Therapy.

Authors:  Mario Bonomini; Luca Piscitani; Lorenzo Di Liberato; Vittorio Sirolli
Journal:  Biomedicines       Date:  2022-04-03

3.  C-reactive protein concentrations are higher in dogs with stage IV chronic kidney disease treated with intermittent hemodialysis.

Authors:  Maria Gabriela Picelli de Azevedo; Silvano Salgueiro Geraldes; Paula Bilbau Sant'Anna; Beatriz Poloni Batista; Suellen Rodrigues Maia; Reiner Silveira de Moraes; Elizabeth Moreira Dos Santos Schmidt; Fabiana Ferreira de Souza; Alessandra Melchert; João Carlos Pinheiro Ferreira; Carmel Rezende Dadalto; Henry David Mogollón García; Priscylla Tatiana Chalfun Guimarães-Okamoto
Journal:  PLoS One       Date:  2022-09-22       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.